André Baruchel

This study uses patient-derived xenografts to identify TP53-associated relapse mechanisms in T-ALL, showing relapse phenotypes linked to OXPHOS metabolism and MYC signaling.

This study identifies CD20 as an actionable target in B-ALL MRD using PDX models and single-cell RNA sequencing, showing anti-CD20 antibodies can eradicate drug-resistant cells.

This paper develops and validates a dual-targeting CAR-T cell therapy for T-ALL that targets CCR9 and CD1a, showing improved efficacy and safety compared to single-targeting approaches.